June 17, 2025 06:00 AM EDTUpdated 08:22 AM

Immuneering says MEK pill beats standard of care in first-line pancreatic cancer

Elizabeth Cairns

Senior biopharma journalist

Immuneering’s oral MEK inhibitor allowed 94% of pancreatic cancer patients in a Phase 2a trial to survive six months when used first-line in combination with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Immuneering says MEK pill beats standard of care in first-line pancreatic cancer

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

J&J dealt blow in fight over its 340B rebate model

A dinner in Paris revived talks for Sanofi's $9.5B deal for Blueprint

FDA loosens safety requirements for CAR-Ts in move to boost access

FDA head Makary’s short-lived CRL ask on KalVista’s drug raises more concerns of political intervention

CEOs push EU to include cell, gene therapy incentives in Biotech Act

Digital Twins in GMP Manufacturing: Shaping the Future of CPV with Aizon

Im­muneer­ing says MEK pill beats stan­dard of care in first-line pan­cre­at­ic can­cer

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

J&J dealt blow in fight over its 340B re­bate mod­el

A din­ner in Paris re­vived talks for Sanofi's $9.5B deal for Blue­print

FDA loosens safe­ty re­quire­ments for CAR-Ts in move to boost ac­cess

FDA head Makary’s short-lived CRL ask on KalVista’s drug rais­es more con­cerns of po­lit­i­cal in­ter­ven­tion

CEOs push EU to in­clude cell, gene ther­a­py in­cen­tives in Biotech Act

Dig­i­tal Twins in GMP Man­u­fac­tur­ing: Shap­ing the Fu­ture of CPV with Aizon

Immuneering says MEK pill beats standard of care in first-line pancreatic cancer

J&J dealt blow in fight over its 340B rebate model

A dinner in Paris revived talks for Sanofi's $9.5B deal for Blueprint

FDA loosens safety requirements for CAR-Ts in move to boost access

FDA head Makary’s short-lived CRL ask on KalVista’s drug raises more concerns of political intervention

CEOs push EU to include cell, gene therapy incentives in Biotech Act

Digital Twins in GMP Manufacturing: Shaping the Future of CPV with Aizon